SET:TU 26 June 2026

June 26, 2026, 7:03 AM EDT. Kymera Therapeutics (KYMR) shares jumped 16.6% to $116.46, driven by early completion of enrollment in its phase IIb BROADEN2 study for atopic dermatitis (AD). This accelerates top-line data release to year-end 2026 from mid-2027, potentially enabling phase III trials by mid-2027. KT-621 has shown promising phase I results, with effective STAT6 protein degradation and clinical benefits. The company anticipates a quarterly loss of $0.64 per share, a 32.6% year-over-year increase, while revenues are expected to rise 232.1% to $38.13 million. Earnings estimate revisions have trended slightly higher, supporting potential near-term price gains. Kymera holds a Zacks Rank #3 (Hold). This momentum highlights growing investor interest in biomedicine stocks amid evolving clinical developments.